Format

Send to

Choose Destination
Nat Rev Gastroenterol Hepatol. 2018 Oct;15(10):606-624. doi: 10.1038/s41575-018-0057-y.

Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer.

Author information

1
Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland.
2
Department of Gynaecological Oncology, University College Dublin School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
3
Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland. carel.leroux@ucd.ie.
4
Investigative Science, Imperial College London, London, UK. carel.leroux@ucd.ie.

Abstract

Metabolic surgery is the best treatment for long-term weight loss maintenance and comorbidity control. Metabolic operations were originally intended to change anatomy to alter behaviour, but we now understand that the anatomical changes can modulate physiology to change behaviour. They are no longer considered only mechanically restrictive and/or malabsorptive procedures; rather, they are considered metabolic procedures involving complex physiological changes, whereby gut adaptation influences signalling pathways in several other organs, including the liver and the brain, regulating hunger, satiation, satiety, body weight, glucose metabolism and immune functions. The integrative physiology of gut adaptation after these operations consists of a complex mechanistic web of communication between gut hormones, bile acids, gut microbiota, the brain and both enteric and central nervous systems. The understanding of nutrient sensing via enteroendocrine cells, the enteric nervous system, hypothalamic peptides and adipose tissue and of the role of inflammation has advanced our knowledge of this integrative physiology. In this Review, we focus on the adaptation of gut physiology to the anatomical alterations from Roux-en-Y gastric bypass and vertical sleeve gastrectomy and the influence of these procedures on food intake, weight loss, nonalcoholic fatty liver disease (NAFLD) and cancer. We also aim to demonstrate the underlying mechanisms that could explain how metabolic surgery could be used as a therapeutic option in NAFLD and certain obesity-related cancers.

PMID:
30181611
DOI:
10.1038/s41575-018-0057-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center